Abstract:Background: Visceral leishmaniasis (VL) is a vector-borne disease caused by parasites and transmitted by sand fly bites, targeted for elimination in India. VL primarily affects rural, low-income populations with limited health care access. In South Asia, few studies have explored patients perspectives, diagnoses, and treatment experiences, and how these experiences influence their expectations about treatment. Methodology/principal findings: A qualitative study was conducted in Bihar, India, using moderator-facilitated, protocol-defined discussion. Eighteen adult patients and 12 caregivers of children diagnosed with and treated for VL within the last 12 months were identified by self-report. Mean time from symptom onset to diagnosis was 13.8 days. Challenges of the patient life experience included lack of urgency by health care professionals, delayed diagnosis, and unavailability of current standard-of-care therapy where a patient receives their diagnosis (63% switched to a different center for treatment, at times delaying treatment). Key barriers include out-of-pocket financial burden, absence from work/home duties, and long-distance travel to hospitals. Patients expressed a preference (29/30) for a potential oral treatment that could be taken close to home over the current standard of care (infusions/injections in clinics). Conclusions/significance: This study reveals new insights and confirms previous research showing access to care for patients with VL in the Bihar area remains a challenge. Although most patients with VL seek care early, diagnosis often requires multiple visits to a health care facility. Despite access to therapy in public hospitals, a substantial number of patients prefer private clinics. Even in public locations, many patients need to move from the diagnostic center to another center to receive therapy, creating an additional burden for patients. As a potential alternative to current parenteral treatment, oral therapy would be preferred by adult patients and caregivers of pediatric patients and may reduce barriers to access to care.

Recent Advances in the Treatment of Leishmaniasis

Current and emerging therapies for the treatment of leishmaniasis

Recent developments and future prospects in the treatment of visceral leishmaniasis

A review on potential therapeutic targets for the treatment of leishmaniasis

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication

Investigational new drugs for the treatment of leishmaniasis

[Risk factors of visceral leishmaniasis in the world: a review]

Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis

Synthetic biology for combating leishmaniasis

Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis

Advances in Leishmania Vaccines: Current Development and Future Prospects

Alternative Non-Drug Treatment Options of the Most Neglected Parasitic Disease Cutaneous Leishmaniasis: A Narrative Review

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis

[Optimization of the control strategy and research priorities to combat the resurgence of visceral leishmaniasis in China]

Epidemiology of Leishmaniasis: Risk factors for its pathology and infection

Efforts toward the Elimination of Visceral Leishmaniasis in South Asia: A Review of Progress in Bhutan

Vaccine candidates against leishmania under current research

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention